Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Shares Outstanding (Diluted Average) (2021 - 2025)

Benitec Biopharma has reported Shares Outstanding (Diluted Average) over the past 5 years, most recently at $43.7 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $43.7 million for Q4 2025, up 34.3% from a year ago — trailing twelve months through Dec 2025 was $43.7 million (up 34.3% YoY), and the annual figure for FY2025 was $36.2 million, up 97.17%.
  • Shares Outstanding (Diluted Average) reached $43.7 million in Q4 2025 per BNTC's latest filing, up from $41.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $43.7 million in Q4 2025 and bottomed at $480688.0 in Q2 2022.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $8.2 million (2021), compared with a mean of $15.6 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) plummeted 92.19% in 2022 before it soared 1225.17% in 2024.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $8.2 million in 2021, then plummeted by 86.17% to $1.1 million in 2022, then skyrocketed by 128.01% to $2.6 million in 2023, then soared by 1164.35% to $32.6 million in 2024, then surged by 34.3% to $43.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for BNTC at $43.7 million in Q4 2025, $41.5 million in Q3 2025, and $36.2 million in Q2 2025.